Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California, specializing in the development and commercialization of treatments for immune-mediated dermatological diseases. Founded in 2016, Arcutis is focused on addressing unmet medical needs in dermatology by leveraging advances in immunology and inflammation. Its lead product candidate, a topical cream formulation of roflumilast, is undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. Additionally, the company is developing other innovative therapies, including a topical foam formulation for seborrheic dermatitis and scalp psoriasis, a selective small molecule inhibitor for hand eczema, and a specialized formulation designed for alopecia areata. Arcutis aims to provide differentiated therapies that effectively tackle persistent treatment challenges in serious skin conditions.
Top Stages
1 past transactions
Ducentis BioTherapeutics
Acquisition in 2022
Ducentis BioTherapeutics Limited is a pre-clinical stage company based in Witney, United Kingdom, focused on developing innovative therapies for inflammation and autoimmune diseases. Established in 2014, the company specializes in modifying a naturally occurring protein that plays a crucial role in immunoregulation. Ducentis targets the CD200/CD200R axis, which provides a deactivating signal to activated immune cells in both the innate and adaptive immune systems. The company's research aims to address various therapeutic needs, including transplant rejection and a range of autoimmune and inflammatory conditions affecting organs such as the lungs, liver, kidneys, eyes, bones, and cartilage.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.